The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1530
ISSUE1530
September 25, 2017
Tocilizumab (Actemra) for Giant Cell Arteritis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tocilizumab (Actemra) for Giant Cell Arteritis
September 25, 2017 (Issue: 1530)
The FDA has approved the interleukin-6 (IL-6) receptor
antagonist tocilizumab (Actemra – Genentech) for
subcutaneous (SC) treatment of giant cell arteritis
in adults. It is the first drug to be approved in the US
for this indication....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.